{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "This retrospective cohort analysis was conducted using data from CIDP patients in the database of Xuanwu Hospital, Capital Medical University between April 2019 and June 2023."
      },
      "Participants": {
        "score": 2,
        "evidence": "using data from CIDP patients in the database of Xuanwu Hospital, Capital Medical University between April 2019 and June 2023."
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study compared the efficacy of tacrolimus plus prednisone (T&P) versus prednisone monotherapy (PM) as maintenance immunosuppressive therapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy and safety of tacrolimus as an add-on therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the response rate, defined as \u22651-point improvement in INCAT score, assessed at 3, 6, and 12 months."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Among 74 screened CIDP patients, 34 (45.9%) were included, with 16 receiving T&P and 18 receiving PM."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All patients completed follow-up (median: 1.4 years; range: 1.0\u20136.5 years)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The T&P group demonstrated significantly higher response rates at 3 and 6 months compared to PM, though this difference attenuated by 12 months."
      },
      "Harms": {
        "score": 1,
        "evidence": "Both groups showed comparable safety profiles, with no serious adverse reactions reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}